BioeXsen GmbH is a biotechnology company focused on innovative molecular technologies, operating in the field of in vitro diagnostics in Germany. It is in a successful and active partnership with Bioeksen R&D Technologies Inc. originated in Turkey, where the research and development studies are carried out.
BioeXsen operates in the fields of production, sales, distribution, installation and technical service of molecular diagnostic products developed with the latest scientific findings and technologies that offer efficient solutions to global health problems. It works in cooperation with Ascopharm GmbH and BioMedical Technology GmbH in production and marketing processes in Germany.
BioeXsen was established to take an active role in fighting the COVID-19 pandemic and aims to provide in vitro diagnostic systems for the detection of not only SARS-CoV-2 but also other pathogenic agents that cause infectious diseases. Accordingly, it carries out studies to increase its production capacity and to serve the entire world.
BioeXsen products based on nucleic acid amplification technology consist of nucleic acid extraction reagents used for sample preparation and real-time polymerase chain reaction. Real-Time PCR kits used for in vitro detection of pathogens allow healthcare providers to identify infections quickly and make critical decisions in a timely manner. Rapid and accurate diagnosis of the causative agents is extremely important for efficient treatment. By using these products, test results with high specificity and sensitivity are obtained in a much shorter time compared to traditional methods. Furthermore, BioeXsen nucleic acid extraction reagents, which are used in the collection, preservation and transfer of clinical samples, provide practical, fast and biosafe solutions for laboratory personnel.
BioeXsen has adopted the principle of carrying out its activities in accordance with national and international laws, directives and standards, considering the satisfaction of its employees and customers. In line with this principle, it works to expand its product portfolio on the basis of the most effective solution and the lowest risk, and to continuously improve the quality, by closely following the molecular technological developments.
